Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (PCSK9i) are highly effective lipid-lowering agents that reduce low-density lipoprotein cholesterol (LDL-C) by enhancing LD

Background: Dyslipidemia, characterized by abnormal blood lipid levels, is a major risk factor for cardiovascular disease, contributing to an estimated 4.2 million deaths and disabilities globally. Th

Atherosclerosis was found in humans who lived thousands years ago. Paleopathologist Marc Armand Ruffer (1859-1917) identified atherosclerotic plaques in the aorta as well as in several large arteries

Background: Although statins remain the cornerstone of lipid-lowering therapy, LDL-C targets are often not achieved with statin monotherapy. This study evaluated the effectiveness and tolerability of

Introduction: Pediatric metabolic screening is governed by a weight-centric dualism that prioritizes obesity while overlooking cardiometabolic risks in undernutrition. While obesity-related dyslipidem